Ranitidine is available widely across Europe as an OTC drug for the short-term relief of acid reflux and/or heartburn. Tests of ranitidine-based drugs have shown that certain products contained N-nitrosodimethylamine, a probable human carcinogen. National regulators in the DACH region are overseeing company-led recalls of OTC and prescription formulations of ranitidine as a precautionary measure. This HBW story covers the probably source of the contaminated ranitidine, the products already being recalled, and the position of other countries. Countries are split between taking immediate action and waiting to see further results of testing.